Start the conversation
The best stocks to buy are the companies that provide must-have products and services that the world can't live without.
The healthcare stock we're bringing you today does just that. It provides medical devices that save lives: more than 50,000 lives to date, in fact.
And that's just the beginning.
The disease this company specializes in is coronary artery disease, which affects more than 100 million people globally each year. It's also the world's No. 1 cause of death. In the United States, heart disease and heart failure together account for one out of every three deaths.
The numbers are only getting worse: The American Heart Association predicts that by 2035, approximately 131 million people in the United States alone will have at least one health problem related to heart disease.
Brace Yourself: The 5G Revolution is unleashing your next potential TRILLION-DOLLAR opportunity – go here now.
But many patients don't qualify for transplants or surgical coronary bypass treatments due to the risks involved.
That's where this company's devices come in.
They can be inserted with a minimally invasive, low-risk procedure to allow patients' hearts to rest and function normally. Recent data from the National Cardiogenic Shock Initiative Study (NCSI) shows that cardiogenic shock patients treated with this procedure have a 72% survival rate (compared to 50% overall) and 98% native heart recovery by the time they are discharged.
All of this points to many more years of success for this essential healthcare stock. But what really makes it stand out is not one, not two, but three separate FDA approvals the company received in May for new devices.
Wall Street has taken notice. One hundred percent of the analysts covering the stock rate it a "Buy" according to FactSet.
And so does our Money Morning Stock VQScore™ system, which just gave this stock a top score.
This will be a great company for years to come. But these new catalysts mean right now is your best chance to capitalize on it.
After Decades of Innovation, This Must-Have Stock Is Getting Injected with New Life
About the Author
Stephen Mack has been writing about economics and finance since 2011. He contributed material for the best-selling books Aftershock and The Aftershock Investor. He lives in Baltimore, Maryland.